Charles Schwab Investment Management Inc. Has $23.70 Million Stake in Ingevity Co. (NYSE:NGVT)

Charles Schwab Investment Management Inc. boosted its holdings in Ingevity Co. (NYSE:NGVT - Free Report) by 9.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 607,628 shares of the company's stock after buying an additional 50,692 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.67% of Ingevity worth $23,697,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in NGVT. Price T Rowe Associates Inc. MD raised its stake in shares of Ingevity by 18.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,218 shares of the company's stock valued at $1,490,000 after purchasing an additional 4,820 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Ingevity by 3.9% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the company's stock worth $326,000 after purchasing an additional 279 shares during the period. Wedge Capital Management L L P NC grew its position in Ingevity by 4.4% in the 2nd quarter. Wedge Capital Management L L P NC now owns 143,493 shares of the company's stock valued at $6,272,000 after buying an additional 6,009 shares in the last quarter. Blue Trust Inc. increased its stake in Ingevity by 101.8% during the 2nd quarter. Blue Trust Inc. now owns 896 shares of the company's stock valued at $43,000 after buying an additional 452 shares during the period. Finally, First Horizon Advisors Inc. raised its position in shares of Ingevity by 809.2% during the 2nd quarter. First Horizon Advisors Inc. now owns 591 shares of the company's stock worth $26,000 after buying an additional 526 shares in the last quarter. Institutional investors and hedge funds own 91.59% of the company's stock.

Ingevity Trading Up 2.4 %

NGVT traded up $1.09 during trading on Friday, reaching $47.11. The company had a trading volume of 237,525 shares, compared to its average volume of 265,302. The firm's 50-day simple moving average is $41.11 and its 200 day simple moving average is $41.70. The company has a debt-to-equity ratio of 6.52, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -2.96 and a beta of 1.62. Ingevity Co. has a 12-month low of $30.90 and a 12-month high of $56.29.

Ingevity (NYSE:NGVT - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.50. The company had revenue of $376.90 million for the quarter, compared to the consensus estimate of $376.95 million. Ingevity had a negative net margin of 38.11% and a positive return on equity of 24.46%. The company's revenue was down 15.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.21 EPS. Equities research analysts anticipate that Ingevity Co. will post 2.55 earnings per share for the current year.

Analysts Set New Price Targets

Separately, BMO Capital Markets boosted their price objective on Ingevity from $40.00 to $47.00 and gave the stock a "market perform" rating in a research note on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $52.17.

About Ingevity

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.